Disease/Condition
335 Clinical Trials
10+ Countries
Diabetes,Diabetes Mellitus, Type 2 Clinical Trials Database - Free Access to 335 Studies
Access comprehensive clinical trial information for Diabetes,Diabetes Mellitus, Type 2 through Pure Global AI's free database. This collection includes 335 clinical trials across multiple phases including Phase 3, N/A, Phase 4. Currently, 1 trials are actively recruiting participants.
Research for Diabetes,Diabetes Mellitus, Type 2 is being conducted in Japan, Germany, United States of America and 7+ other countries. Leading sponsors include Novo Nordisk A/S and Emory University. Pure Global AI offers free access to clinical trial data from ClinicalTrials.gov, WHO ICTRP, and regional registries worldwide.
Free Database
Powered by Pure Global AI
840K+ Global Trials
Updated Daily
By Phase
Phase 3
130N/A
78Phase 4
63Phase 1
45Phase 2
19By Status
Completed
318Terminated
13Withdrawn
2Not yet recruit...
1Recruiting
1Top Countries
Japan29
Germany25
United States of America23
China23
Denmark8
Top Sponsors
Novo Nordisk A/S332
Emory University2
MedsPLUS Consultin...1
Recent Trials
Latest clinical trials for Diabetes,Diabetes Mellitus, Type 2
NCT05958602
Not yet recr...
Improving Recruitment and Retention for Diabetes Self-Management Education and Support
MedsPLUS Consulting
NCT04818242
Recruiting
Dexcom CGM in Long-term Care
Emory UniversityUnited States of America
NCT04160078
Completed
Mindfulness IN-home for Diabetes and Sleep Health
Emory UniversityUnited States of America
NCT03466567
Phase 1
Completed
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects
Novo Nordisk A/SGermany
NCT03374774
Completed
A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)
Novo Nordisk A/SIndia
NCT03292185
Phase 1
Completed
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
Novo Nordisk A/SChina
NCT03288740
Phase 1
Completed
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
Novo Nordisk A/SChina
NCT03268005
Phase 3
Completed
Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes
Novo Nordisk A/SArgentina,Bulgaria,Canada,Croatia,Czech,Germany,Greece,Italy,South Korea,Poland,Puerto Rico,Romania,
NCT03191396
Phase 3
Completed
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Novo Nordisk A/SBulgaria,Czech,Finland,France,Germany,Hungary,Italy,Poland,Slovenia,Spain,Sweden,United Kingdom
NCT03172494
Phase 3
Completed
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Novo Nordisk A/SChina
NCT03175120
Phase 3
Completed
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
Novo Nordisk A/SChina,China
NCT03136484
Phase 3
Completed
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
Novo Nordisk A/SArgentina,Brazil,Canada,India,Ireland,Italy,Lebanon,Malaysia,Mexico,Sweden,United Kingdom,United Sta
NCT03086330
Phase 3
Completed
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/SAustria,Canada,Japan,Norway,Puerto Rico,Russian Federation,United States of America
NCT03078478
Phase 3
Completed
A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
Novo Nordisk A/SCanada,Denmark,Estonia,Germany,Greece,Hungary,Norway,Poland,Puerto Rico,Romania,Serbia,United States
NCT03070704
Withdrawn
Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India
Novo Nordisk A/S
NCT03061214
Phase 3
Completed
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)
Novo Nordisk A/SBrazil,China,China,South Korea,South Africa,Taiwan,Ukraine
NCT03021187
Phase 3
Completed
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin
Novo Nordisk A/SCanada,France,Greece,India,Japan,Mexico,Poland,Puerto Rico,Russian Federation,United States of Ameri
NCT03015220
Phase 3
Completed
Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/SJapan
NCT03018028
Phase 3
Completed
Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes
Novo Nordisk A/SJapan
NCT02964104
Phase 1
Completed
A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes
Novo Nordisk A/SGermany
About Diabetes,Diabetes Mellitus, Type 2 Research
Pure Global AI provides free access to 335 clinical trials studying Diabetes,Diabetes Mellitus, Type 2, aggregated from major global registries including ClinicalTrials.gov, WHO ICTRP, and regional databases.
The trials span multiple phases, from early Phase 1 safety studies to large-scale Phase 3 efficacy trials, conducted across 10+ countries.
Top research sponsors include Novo Nordisk A/S, Emory University, MedsPLUS Consulting, among others.
Quick Facts
Total Trials335
Countries10+
Sponsors3+
Recruiting1